Status:
UNKNOWN
Individualization Flow in Patients Treated With High Flow Nasal Therapy (iFLOW)
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Conditions:
High-Flow Nasal Cannula
Oxygen Therapy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In patients with acute hypoxemic respiratory failure (AHRF), High Flow Nasal Therapy (HFNT) improves oxygenation, tolerance, and decreases work of breathing as compared to standard oxygen therapy by f...
Eligibility Criteria
Inclusion
- Adult patient admitted to the ICU requiring NHF due to AHRF that will be defined as an SpO2/FIO2 ratio \<315
Exclusion
- Patient with indication for immediate CPAP, NIV, or invasive mechanical ventilation
- Hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine \> 1 mg/h
- Severe acidosis (pH ≤ 7.25)
- Pregnant woman
- Tracheotomised patient
- Formalized ethical decision to withhold or withdraw life support
- Patient under guardianship
- Patient deprived of liberties
- Patient already enrolled in the present study in a previous episode of acute respiratory failure
- Patient who does not consent.
Key Trial Info
Start Date :
March 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2023
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT05401474
Start Date
March 18 2022
End Date
February 28 2023
Last Update
June 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035